LIN YANG
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer (NCT06711471) | LIN YANG | 2024-11-14 |
Track LIN YANG automatically
Every clearance here is in the API, with alerts when new ones post.